Teva shares approach 20-year low amid Moody’s warning and other woes

Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with challenges ranging from opioid lawsuits to a congressional price-fixing probe to declining sales of its MS drug Copaxone. Investors were none too happy.